These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 19030021

  • 1. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW, Wiedey K.
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [Abstract] [Full Text] [Related]

  • 2. Leuprorelin acetate in prostate cancer: a European update.
    Persad R.
    Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
    [Abstract] [Full Text] [Related]

  • 3. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND, Guerrero S, Sanahuja RM, Gambús G, Parente A.
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [Abstract] [Full Text] [Related]

  • 4. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS.
    J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
    [Abstract] [Full Text] [Related]

  • 5. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
    Khan MS, O'Brien A.
    Urol Int; 1998 Feb; 60(1):33-40. PubMed ID: 9519419
    [Abstract] [Full Text] [Related]

  • 6. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R, Bello U.
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [Abstract] [Full Text] [Related]

  • 7. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F.
    Urol Int; 1998 Apr; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [Abstract] [Full Text] [Related]

  • 8. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T, Aso Y, Akaza H, Fujita K, Fuse H, Hosaka M, Isurugi K, Kamidono S, Katayama T, Kawabe K.
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS, Pacificar JS, Shapiro CE, Williams SG.
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
    Fornara P, Jocham D.
    Urol Int; 1996 Jun; 56 Suppl 1():18-22. PubMed ID: 8776813
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.
    Suzuki K, Namiki M, Fujimoto T, Takabayashi N, Kudou K, Akaza H.
    Jpn J Clin Oncol; 2015 Dec; 45(12):1168-74. PubMed ID: 26486824
    [Abstract] [Full Text] [Related]

  • 15. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K, Akaza H, Naito S, Usami M, Tsukamoto T, Shimazaki J, Kotake T, Yamanaka H, Oohashi Y, Yoshinaka R, Onouchi H, Yokokawa K.
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot].
    Jiménez Cruz JF, Vera Donoso CD, Iborra I, Solsona E, Forner E, Villavicencio H, Díaz C, González C, Rioja L, Pertusa C.
    Actas Urol Esp; 1994 Feb; 18(2):90-3. PubMed ID: 7976707
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
    Sharifi R, Knoll LD, Smith J, Kramolowsky E.
    Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.